Sandoz gains FDA approval of a generic of anti-clotting drug Lovenox

07/25/2010 | Wall Street Journal, The

Novartis' Sandoz unit obtained FDA approval to market enoxaparin sodium, a copy of Sanofi-Aventis' injectable anti-clotting treatment Lovenox. "Sandoz is the first company to launch generic enoxaparin sodium in the U.S., delivering on our strategy of being first to market with key products and underscoring our leadership in differentiated products," a company official said.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC